Michael Givertz
Corporate Officer/Principal bij Cardioxyl Pharmaceuticals LLC
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Douglas Cowart | M | - |
Cardioxyl Pharmaceuticals LLC
Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | 19 jaar |
Kimberly McCutcheon Jablonski | F | - |
Cardioxyl Pharmaceuticals LLC
Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
Jeff Bank Clark | M | 67 |
Cardioxyl Pharmaceuticals LLC
Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
Peter Thompson | M | 64 |
Cardioxyl Pharmaceuticals LLC
Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
Robert J. Garland | M | - |
Cardioxyl Pharmaceuticals LLC
Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
Gary L. Stiles | M | - |
Cardioxyl Pharmaceuticals LLC
Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
Michael Barrett | M | 81 |
Cardioxyl Pharmaceuticals LLC
Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
Shi Yin Foo | M | - |
Cardioxyl Pharmaceuticals LLC
Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | 11 jaar |
Ronald Borchardt | M | - |
Cardioxyl Pharmaceuticals LLC
Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
John Fukuto | M | - |
Cardioxyl Pharmaceuticals LLC
Cardioxyl Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardioxyl Pharmaceuticals, Inc. discovers and develops therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded by Vincent J. Kalish and Douglas Cowart in 2005 and is headquartered in Chapel Hill, NC. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 10 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Michael Givertz
- Persoonlijk netwerk